WO2005030938A1 - 発酵及び培養方法、植物発酵エキス、植物発酵エキス末並びに該植物発酵エキス配合物 - Google Patents
発酵及び培養方法、植物発酵エキス、植物発酵エキス末並びに該植物発酵エキス配合物 Download PDFInfo
- Publication number
- WO2005030938A1 WO2005030938A1 PCT/JP2004/013812 JP2004013812W WO2005030938A1 WO 2005030938 A1 WO2005030938 A1 WO 2005030938A1 JP 2004013812 W JP2004013812 W JP 2004013812W WO 2005030938 A1 WO2005030938 A1 WO 2005030938A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fermentation
- extract
- fermented
- plant
- wheat
- Prior art date
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 92
- 230000004151 fermentation Effects 0.000 title claims abstract description 92
- 238000012136 culture method Methods 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims description 24
- 239000000843 powder Substances 0.000 title claims description 22
- 239000000419 plant extract Substances 0.000 title abstract description 14
- 241000209140 Triticum Species 0.000 claims abstract description 157
- 235000021307 Triticum Nutrition 0.000 claims abstract description 155
- 241000196324 Embryophyta Species 0.000 claims abstract description 70
- 235000013312 flour Nutrition 0.000 claims abstract description 54
- 241000894006 Bacteria Species 0.000 claims abstract description 27
- 239000000463 material Substances 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000000284 extract Substances 0.000 claims description 189
- 230000000694 effects Effects 0.000 claims description 56
- 230000003308 immunostimulating effect Effects 0.000 claims description 38
- 229920002472 Starch Polymers 0.000 claims description 24
- 210000002540 macrophage Anatomy 0.000 claims description 24
- 235000019698 starch Nutrition 0.000 claims description 22
- 239000008107 starch Substances 0.000 claims description 22
- 241001474374 Blennius Species 0.000 claims description 21
- 240000007594 Oryza sativa Species 0.000 claims description 19
- 235000007164 Oryza sativa Nutrition 0.000 claims description 19
- 235000009566 rice Nutrition 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 108010093965 Polymyxin B Proteins 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 17
- 229920000024 polymyxin B Polymers 0.000 claims description 17
- 229960005266 polymyxin b Drugs 0.000 claims description 17
- 241000520272 Pantoea Species 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 13
- 235000018927 edible plant Nutrition 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 9
- 235000013376 functional food Nutrition 0.000 claims description 9
- 239000003788 bath preparation Substances 0.000 claims description 8
- 235000013339 cereals Nutrition 0.000 claims description 8
- 244000052616 bacterial pathogen Species 0.000 claims description 7
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 6
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 6
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 4
- 239000000273 veterinary drug Substances 0.000 claims description 4
- 241000607720 Serratia Species 0.000 claims description 3
- 235000015099 wheat brans Nutrition 0.000 claims description 3
- 241000588921 Enterobacteriaceae Species 0.000 claims description 2
- 240000006439 Aspergillus oryzae Species 0.000 claims 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims 1
- 238000012364 cultivation method Methods 0.000 claims 1
- 241000588912 Pantoea agglomerans Species 0.000 abstract description 29
- 230000008569 process Effects 0.000 abstract description 4
- 238000011109 contamination Methods 0.000 abstract description 3
- 239000012535 impurity Substances 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000002434 immunopotentiative effect Effects 0.000 abstract 1
- 230000000091 immunopotentiator Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 239000002158 endotoxin Substances 0.000 description 33
- 229920006008 lipopolysaccharide Polymers 0.000 description 33
- 244000005700 microbiome Species 0.000 description 33
- 239000000126 substance Substances 0.000 description 31
- 241000239218 Limulus Species 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 238000004519 manufacturing process Methods 0.000 description 26
- 102100040247 Tumor necrosis factor Human genes 0.000 description 24
- 239000002609 medium Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 239000013543 active substance Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 239000008213 purified water Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 241000251468 Actinopterygii Species 0.000 description 11
- 229930186217 Glycolipid Natural products 0.000 description 11
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 10
- 239000006071 cream Substances 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 206010012438 Dermatitis atopic Diseases 0.000 description 8
- 201000007100 Pharyngitis Diseases 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 201000008937 atopic dermatitis Diseases 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 239000002054 inoculum Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 8
- 239000004382 Amylase Substances 0.000 description 7
- 102000013142 Amylases Human genes 0.000 description 7
- 108010065511 Amylases Proteins 0.000 description 7
- 241000271566 Aves Species 0.000 description 7
- 241000252233 Cyprinus carpio Species 0.000 description 7
- 235000019418 amylase Nutrition 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 206010068319 Oropharyngeal pain Diseases 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 241001261506 Undaria pinnatifida Species 0.000 description 6
- 238000009360 aquaculture Methods 0.000 description 6
- 244000144974 aquaculture Species 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000001629 sign test Methods 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
- 108010040201 Polymyxins Proteins 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000006433 tumor necrosis factor production Effects 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 241000938605 Crocodylia Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 244000144977 poultry Species 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 239000006562 flour medium Substances 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 241001051708 Cyprinid herpesvirus 3 Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- -1 glucose and fructose Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940094952 green tea extract Drugs 0.000 description 2
- 235000020688 green tea extract Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000013529 tequila Nutrition 0.000 description 2
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 241000357202 Dendrobium linguiforme Species 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001605853 Fishia Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 241000276699 Seriola Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 230000037366 wrinkle cream Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Definitions
- Fermentation and culture method plant fermented extract, plant fermented extract powder, and plant fermented extract blend
- the present invention relates to mammals including humans (specifically, domestic animals, pets, etc.), birds (specifically, poultry, pets, etc.), amphibians, reptiles, fish (specifically, aquaculture) Fish, pets, etc.), invertebrate drugs, veterinary drugs, quasi-drugs, cosmetics, foods, functional foods, feeds, bath additives, etc. Fermentation and culture method, plant fermentation extract production method, fermented plant-containing extract obtained by fermentation and culture method, immunostimulatory substance-containing powder obtained from the plant fermented extract, and plant fermentation
- the present invention relates to a fermented plant extract composition containing an extract.
- fermentation technology using microorganisms is widely used not only in the food field but also in a wide field.
- wine and other alcoholic beverages, soy sauce and miso, cheese It covers a wide range of fields such as fermented milk products and pharmaceuticals.
- the microorganisms used in these fermentations are wide-ranging, and representative examples include potato (fungal) yeast and lactic acid bacteria. However, most of those using gram-negative bacteria have been reported.
- fermentation is a phenomenon in which organic matter is decomposed by the action of microorganisms, and broadly means production of useful substances by microorganisms (Non-patent Document 3).
- a typical fermentation technology using microorganisms is wine.
- Wine is a fermentation technique using wine yeast attached to the grape skin, and the product is alcohol.
- Gram-negative bacteria using methane fermentation using methane bacteria Gram-negative bacteria using methane fermentation using methane bacteria
- Ryu tongue orchid's rhizome power ethanol fermentation (tequila production) is known, but edible plants are used as raw materials, and fermentation culture using microorganisms characterized by symbiosis exclusively with the plant is mostly known
- No immunostimulatory substance has been noted as a fermentation product. In fact, fermentation and culture methods aimed at producing immunostimulatory substances have never attracted attention.
- microorganisms when fermentation is performed with microorganisms, there are generally nutritional conditions that must be satisfied by the fermentation substrate for the growth of microorganisms.
- the existence of substances that can be used as nutrients by microorganisms such as sufficient monosaccharides such as glucose and fructose, is essential as a carbon source.
- it can be used as a fermentation substrate without any additional processing, such as fruits that are naturally rich in fructose. Is required.
- Zymomonasu mobilis is a microorganism that is used in the production of tequila.
- Non-patent Document 4 there is a document describing that starch cannot be decomposed (Non-patent Document 4).
- Pantoea agglomerans is a symbiotic bacterium symbiotic to wheat and is considered to be a useful fungus for wheat cultivation because it supplies phosphorus and nitrogen to wheat (Non-patent Document 7).
- Pantoea agglomerans is attached not only to wheat but also to the skin of pear and apple fruits, and it has been clarified in Europe that mold rot can prevent mold rot.
- Development is progressing in which fungi are non-toxic and are used as fungicides that are friendly to the natural environment (Non-patent Document 8).
- the symbiosis is “a phenomenon in which different organisms live together. In this case, a behavior that is mutually active means that a physiologically close connection is constantly maintained!
- Non-patent Document 9 Non-patent Document 9
- the low-molecular-weight lipopolysaccharide obtained from this fungus has a preventive effect on various diseases (diabetes, hyperlipidemia, atopic dermatitis, cancer) of human mice, fish, crustaceans and birds. It is found that it is effective in preventing infection (Patent Document 3, Non-Patent Document 2).
- Patent Document 3 Non-Patent Document 2.
- Pantoea agglomerans is cultured at low cost using a medium in which the main component of the protein contained in the culture solution is derived from plants, and the plant components are fermented.
- Pantoea contained in plants' Agglomerans or materials containing a large amount of fermentation products are prepared and used to make mammals including humans (specifically, domestic animals, pets, etc.), birds (specific , Chickens, pets, etc.), amphibians, reptiles, fish (specifically, aquaculture, pets, etc.), invertebrate drugs, veterinary drugs, quasi drugs, cosmetics, functionalities
- mammals including humans (specifically, domestic animals, pets, etc.), birds (specific , Chickens, pets, etc.), amphibians, reptiles, fish (specifically, aquaculture, pets, etc.), invertebrate drugs, veterinary drugs, quasi drugs, cosmetics, functionalities
- wheat flour is a complex organic substance such as starch that exists in wheat grains, but it is separated from the wheat symbiotic microorganism Pantoeia-Agglomerans by the outer skin and has no direct contact.
- agglomerans can be fermented and cultured with wheat flour cannot be clarified in connection with the fact that microorganisms live together with wheat, and in fact that pantoea agglomerans can assimilate flour Has not been known so far and has never been reported.
- Pantoea agglomerans cannot use wheat starch as a fermentation substrate.
- the known technology can be regarded as fermentation, which is simply intended to effectively use the amylase activity of microorganisms, and the growth of microorganisms using starch as a substrate is not planned. Nah ...
- fermented products are produced in addition to the growth of microorganisms by using starch as the only carbon source, and this example is not a simple fermentation but a fermentation culture. Different.
- a plant fermented extract containing a large amount of an immunostimulatory substance hereinafter referred to as “pantoair agromerans” and containing flour as a main component
- Plant fermented extract obtained by fermenting and culturing in a medium is called wheat fermented extract.
- wheat fermented extract If it can be produced at low cost, as a specific example, human, livestock's aquaculture is safe and environmentally friendly and can prevent infection It should be possible to provide effective medicines, veterinary medicines, quasi drugs, cosmetics, foods, functional foods, feeds and bath preparations.
- the present invention has been completed by repeating many experiments on the basis of the newly discovered that Pantoea agglomerans grows with flour as a substrate.
- the plant fermentation extract provided by the present invention is a culture liquid obtained by fermentation and culture, a liquid component obtained by solid-liquid separation, and a solid component obtained by solid-liquid separation. It is a generic name for liquid components obtained by adding a process. That is, the plant fermentation extract is a culture solution itself obtained by the fermentation and culture method according to the present invention, and
- the plant fermented extract can be dried and used as a plant fermented extract powder, or the plant fermented extract powder can be used by dissolving it in an appropriate solution such as a phosphate buffer containing physiological saline.
- Patent Document 1 Japanese Patent Laid-Open No. 3-218466
- Patent Document 2 JP-A-8-198902
- Patent Document 3 WO00 / 57719
- Patent Document 4 JP-A-6-78756
- Patent Document 5 Japanese Patent Laid-Open No. 4-187640
- Patent Document 6 Japanese Patent Laid-Open No. 4-49240
- Patent Document 7 Japanese Patent Laid-Open No. 4-99481
- Patent Document 8 JP-A-5-155778
- Non-Patent Document 1 Hiroyuki Inagawa, 8 people, “Biotherapy”, 1991, No. 5, 4, p617-621 Special ⁇ 12: 3 ⁇ 4oma, u-I., 1 other, Tumor Necrosis Factor: Molecular and ellular
- Non-Patent Document 3 Tsuneo Yamada and 6 others, “Biological Encyclopedia 3rd Edition", 1983, pl021
- Non-Patent Document 4 Gavini, F. and 6 others, “Int. J. Syst. BacterioL", 1989, 39th,
- Non-Patent Document 5 Nishizawa, T. and others, "Chem. Pharm. Bull.”, 1992, No. 40, No. 2, P479-483
- Non-Patent Document 6 Inagawa, H. and 8 others, "Chem. Pharm. Bull.”, 1992, No. 40, No. 4, P994-997
- Non-patent literature 7 Neilson, AH ⁇ J. Appl. Bacteriol. ", 1979, 46 ⁇ , 3, p483-491
- Non-patent literature 8 Nunes, C. et al.,” Int. J. Food Microbiol “, 2001, 70th, 1st, 2nd merger, p53-61
- Non-Patent Document 9 Tsuneo Yamada and 6 others, “Biological Encyclopedia 3rd Edition”, 1983, p287-288
- Non-Patent Document 10 Nunes, C. and 4 others, J. Appl. Microbiol ”, 2002, No. 92, No. 2, P247-255
- Non-patent literature l l Asis, C. A. Jr. and others, "Lett. Appl. Microbiol.” 2004, No. 38, No. 1, pl9-23
- Non-Patent Document 12 Vanneste, 3 outside JL, “J. Bacteriol.” 1992, No. 174, 9, P2785-2796
- Non-Patent Document 13 Kearns, 1 outside LP, "Appl Environ Microbiol.” 1998, 64th, No. 5, pl837-1844
- the immunostimulatory substance is often a constituent component or product of a microbial organism that coexists with a plant itself or a plant. Therefore, if an immunostimulatory substance derived from a natural product that is safe even if ingested is obtained, the ability of the edible plant itself to extract components (for example, Limulus-positive glycolipid, Patent Document 1) It is useful to cultivate efficiently to obtain its constituents or products (for example, low molecular weight lipopolysaccharide, Patent Document 2).
- the amount of the immunostimulatory substance contained in the edible plant must be very large, and the intake of the immunostimulatory material must be kept appropriate. However, since it is generally not easy, the effect cannot be expected.
- plant moss is extracted and used as food or medicine, it is expensive and poor in practicality.
- Pantoea agglomerans a wheat symbiotic bacterium
- Pantoea agglomerans contains a low-molecular-weight lipopolysaccharide effective for immunostimulation as a constituent component.
- the main component of the protein contained in the culture medium is animal-derived, such as NZ Aminya tryptone or casamino acid, and pantoea agglomerans is cultured.
- the present invention provides a fermentation and culture method capable of obtaining an immunostimulatory substance efficiently at low cost using a safe material, a plant fermentation extract obtained by the method, and a plant fermentation extract. It is an object of the present invention to provide a plant fermented extract powder obtained and a plant fermented extract blend blended with the plant fermented extract powder.
- materials derived from edible plants are exclusively symbiotic to plants. It is characterized by being fermented with facultative anaerobic gram-negative bacteria and simultaneously culturing the facultative anaerobic gram-negative bacteria.
- Fermentation and culture can be performed in a simple process by fermenting starch as a carbon source with the facultative anaerobic gram-negative bacteria.
- the facultative anaerobic gram-negative bacterium is facultative anaerobic bacilli.
- the facultative anaerobic bacilli belong to the genus Pantoea, Serratia, or Enterobacter.
- the facultative anaerobic bacilli are Pantoea agglomerans, so that starch can be used as a carbon source.
- the edible plant is preferably cereal, seaweed, legumes, or a mixture thereof.
- the material derived from the grain is preferably wheat flour, rice flour, wheat bran flour, rice bran, or sake lees.
- wheat flour contains dartene as a protein source, it can be efficiently fermented and cultured without using animal-derived materials.
- the material derived from the seaweed is seaweed powder, seaweed powder, or kelp powder.
- the material derived from the beans is okara, since it contains a large amount of protein, it can be efficiently fermented and cultured without using animal-derived materials.
- the fermented plant extract of the present invention is obtained by the fermentation and culture method.
- the plant fermented extract powder of the present invention is characterized in that the plant fermented extract power is also obtained.
- the plant fermented extract blend of the present invention is characterized in that the plant fermented extract or plant fermented ex-powder is blended.
- the plant fermented extract blend may be a pharmaceutical, veterinary pharmaceutical, quasi-drug, cosmetic, food, functional food, feed, or bath preparation.
- the fermented plant extract exhibits the following physical properties. [0030] Even in the presence of polymyxin B, it exhibits macrophage activity. The fermented plant extract has an immunostimulatory effect.
- culture can be performed in a medium that does not contain animal-derived components, there is no problem of contamination with animal component-derived impurities, so there is a risk of contamination with BSE or unknown harmful substances, for example.
- a method for producing a plant fermented extract that is highly safe and can be used for various purposes at low cost, and can produce an immunostimulating substance-containing plant fermented extract or plant fermented extract powder safely and inexpensively, Furthermore, the culture solution, immunostimulatory substance and extract and extract powder, as well as pharmaceuticals, veterinary drugs, quasi-drugs, cosmetics, foods, functional foods, feeds and bath preparations containing the extract or extract powder are provided. Can do.
- TNF-inducing activity TNF-inducing activity
- the immunostimulatory effect can be quantified by the amount of TNF produced. Therefore, we examined the production of TNF from macrophages using Limulus-positive plant glycolipids derived from wheat flour and low molecular weight lipopolysaccharide derived from Pantoea agglomerans. In all of the examples, the molecular weight lipopolysaccharide has the ability to prevent the production of TNF from macrophages by treatment with polymyxin B.
- the fermented plant extract of the present invention produces TNF from macrophages even when the same treatment is applied. Indicated. This is because the plant fermentation extract of the present invention obtained as a result of fermentation and culture is qualitatively different from the immunostimulatory effect of the plant itself and the components of the microorganism used for fermentation. It shows having different immunostimulatory effects.
- FIG. 1 is a diagram showing the effect of suppressing the development of koi herpes by a feed containing fermented wheat extract. is there.
- macrophage activity was evaluated by TNF production from macrophages as an index of the immunostimulatory action exhibited by the fermented wheat extract.
- Low molecular weight lipopolysaccharide is extremely safe and superior in biological activity compared to general-purpose high-molecular-weight lipopolysaccharide (hereinafter referred to as normal lipopolysaccharide). ing. Therefore, the low molecular weight lipopolysaccharide content was measured. Low molecular weight lipopolysaccharide is described in detail in Patent Document 2. Although this example relates to fermented wheat extract, the present invention does not mean that the plant is limited to wheat and the immunostimulatory substance is limited to low molecular weight lipopolysaccharide.
- Pantoea 'agglomerans can be cultured using a known method.
- Patent Document 2 Non-Patent Document 8
- the main component of the protein contained in the known culture medium is derived from animals, and the cost of the medium is high.
- BSE the inclusion of animal-derived impurities becomes a problem from the viewpoint of food safety, as represented by BSE.
- the manufacturing cost is high and it is not a sufficient method from the practical point of view.
- the present inventors conducted an example of a fermentation and culture method using pantoea agglomerans to obtain a wheat fermented extract.
- the main component of the protein contained in the culture medium has been conventionally derived from animals, but the present invention has made it derived from plants.
- a product obtained by degrading a protein such as casein derived from milk with digestive enzymes is added to the culture solution.
- the cost per medium 11 is about 250 yen, but if this can be replaced with flour, the cost will be about 16 yen. So far, fermentation has not been carried out for the purpose of synergistic fusion while increasing the immunostimulatory activity of both the plant and the microorganisms that live with it.
- the present invention provides a large amount of immunostimulatory substances that are not limited to pantoea agglomerans as microorganisms described in the examples, wheat as edible plants or wheat as a material. It can also be applied to ingredients that are obtained from other edible plants, such as seaweed, such as seaweed, and cereals (including wheat flour, rice flour, wheat bran flour, rice bran, sake lees etc. ), Seaweed (including seaweed-derived materials such as wakame flour, mekabu flour, or kelp powder), beans (including okara, etc., derived from beans) are also applicable. These plants are well known to contain proteins and sugars!
- Non-patent Document 4 Non-patent Document 4
- the product can also be adapted to facultative anaerobic gram-negative bacteria that coexist with these plants.
- the wheat fermented extract itself is a novel substance that has an immunostimulatory effect by fusing wheat, its symbiotic bacterium, Pantoea agromerans, and fermented products by combining these yarns.
- the present invention is not limited to this.
- Pantoea 'agglomerans is isolated from wheat flour according to a conventional method (Non-patent Document 1). Once isolated and identified, this bacterium can be stored in 50% glycerol or the like.
- Ferment 9 at 40 ° C. In some cases, it may be shaken if left standing. You can also stir every few hours.
- the precipitate can be used as a fermented wheat flour, as it is, or as a raw material to be mixed with the feed.
- the fermented wheat extract produced in 14 can be further refined depending on the application.
- 14 salts are mixed with salt such as sodium chloride so that the final concentration is 0.05-1 mol / 1, and then a solvent such as ethanol is added in an amount 1 to 13 times that of the extract. Precipitation occurs. You may collect this with a centrifuge. This precipitate may be further washed with a solvent such as ethanol. If this is dried, it can also be made into powder.
- pantoea agglomerans In order to confirm the ability of pantoea agglomerans, a wheat resident symbiotic bacterium, to grow using wheat flour as a carbon source, the growth of pantoea agglomerans in flour solid media was examined.
- the wheat flour fermentation solution of 7 was centrifuged (Hitachi, high-speed cooling centrifuge SCR-20B, 5000 rpm, 20 minutes, 4 ° C), and the precipitate was collected.
- Phosphate buffer solution was added to the precipitate in 8 and suspended to make a total volume of 100 ml, transferred in 33 ml portions to a 50 ml centrifuge tube, and extracted by heating in a boiling water bath for 30 minutes. After completion of heating, the mixture was cooled to room temperature and centrifuged (Hitachi, high-speed cooling centrifuge SCR-20B, 10000 rpm, 20 minutes, 20 ° C). After centrifugation, 82 ml of a pale yellow supernatant was decanted and collected in another container.
- Iodine starch reaction Iodine reagent 1N (12.7 g iodine, 10 g water in 25 g potassium and 25 ml gale, mix well, then add water to make 100 ml) Dilute it 200 times, and mix well with 0.1 1 ml of fermented wheat extract previously dissolved to a concentration of lmgZml. The fermented wheat extract immediately showed light purple color and dark purple color (positive).
- Table 6 summarizes the results of Limulus positive glycolipid and low molecular weight lipopolysaccharide.
- fermented wheat extract is limulus-positive glycolipid
- low-molecular-weight lipopolysaccharide is protein content, sugar content, nucleic acid content (except for limulus-positive glycolipid because there is no data)
- limulus activity It is clear that the substance content and iodine starch reaction are all different, and the substance is clear.
- Table 7 That is, the fermented plant extract of this example is a novel one, unlike the rimlas positive glycolipid and the low molecular weight lipopolysaccharide, in that it exhibits the following respective physical properties. It contains 5-15% protein, 20-45% sugar, 10-35% nucleic acid, and 10-40% Limulus positive substance, is positive for iodine starch reaction, and has macrophage activity even in the presence of polymyxin B. Shows ability.
- a 48-well plate was charged with TH P-1 (1 ⁇ 10 6 cells / 250 1: 10% urine fetal serum RPMI1640 medium) used as human macrophages and pre-cultured for 30 minutes in advance.
- Medium 250 1 (final amount 500 ⁇ 1) was added so that the final concentration of each sample was 1 lOOOOngZml.
- a feed containing 430 gZkg of the fermented wheat extract produced in Example 2 was prepared. Grant As chickens, broiler commercial chickens were used in groups of about 5500-6000 chickens. The control test category does not include fermented wheat extract! /, Feed. Administration of fermented wheat extract was started at 3 weeks after hatching and was administered daily until 7 weeks of age. The number of dead animals was measured daily. Chickens that did not meet the standards at the time of shipment were discarded. The results are shown in Table 9. The removal rate in the test plot (feed with fermented wheat extract) was 1.9%, reaching 3.3% in the low control plot. The breeding rate was 98.1% in the test plot and 96.7% in the control plot, so an improvement of 1.4% was observed.
- Coy Magoy weighing 70g was used. The test was conducted with 20 animals per group.
- koi herpesvirus Eat the koi ella lg killed by koi herpes infection, add 10 ml of Hanks balanced salt solution (HBSS) buffer, homogenize, filter through 0.45 micron filter, The filtrate was used as a virus solution.
- HBSS Hanks balanced salt solution
- Feeding method Each feed was fed once a day at a weight of 1% per body weight. This corresponds to 0, 50, 100, 200 / z g / kg body weight / day, respectively, when converted to the fermented wheat extract.
- Example 2 About 10% of the fermented wheat extract produced in Example 2 was added to and mixed with the fat-soluble base material 1 ointment according to the formulation shown in Table 11 to obtain an ointment.
- Group A was dissolved by heating at 70 ° C, dissolved in 1Z4 amount of purified water and dissolved in B at 70 ° C, and Group B dissolved in 1Z4 amount of purified water and dissolved at 70 ° C by heating. Mix well with a homogenizer, cool to 40 ° C, add group D to adjust the pH to 6.8, add the remaining purified water and the fermented wheat extract produced in Example 2 and mix thoroughly. Get the emulsion.
- the fermented wheat extract should be dissolved in purified water in advance so as to reach 5 mgZml, and 0.1 ml of the milk lOOg should be added.
- a questionnaire survey was conducted by 43 men and women using this cream. As a result, 18 respondents answered that the moisturizing effect was indeed effective, 18 responded that the effect was somewhat effective, 2 responded that there was no effect, and 5 respondents left blank (one sample). Sign test: P ⁇ 0.0001). About 6 people who answered that it is effective and good, 13 people answered that it was effective, 0 people answered that there was no effect, and 24 people left blank. there were . (One-sample sign test: P 0. 0001). There were no respondents who answered that there was a bad skin symptom after use. In addition, a questionnaire survey was conducted with four people with mild atopy-like symptoms using this cream. Three people answered that it was indeed effective in improving atopic dermatitis.
- this cream was used for burn patients.
- the cream containing the fermented wheat extract produced in Example 2 was applied to one hand, and the wrinkle cream containing no fermented wheat extract was applied to the other hand.
- the hand that applied the cream containing the fermented extract recovered clearly faster.
- this topical application was applied to 10 burn patients, the wounds recovered faster when the cream containing the fermented wheat extract was applied externally than when the cream without the fermented wheat extract was applied externally (Fishia's direct Probability: P (0.0001). From the above, this fermented wheat extract was shown to have a therapeutic effect on burns.
- the ingredients used are shown in Table 13.
- the fermented wheat extract the fermented wheat wheat prepared in Example 2 is dissolved in purified water in advance to a concentration of 5 mgZml, and 0.1 ml of the lotion is added to lOOg.
- a bath preparation containing fermented wheat extract was prepared for the purpose of improving biological functions.
- Table 14 shows the basic components of the bath preparation.
- a bath containing fermented wheat extract was prepared by adding 110 / z g of the fermented wheat extract produced in Example 2 to the above components. 102 subjects were given a blinded and non-extracted control, and used in a normal bath (160-200 liters) when bathing (1) warming of the body, (2) hot water cooling. Difficulty, (3) fatigue recovery effect, (4) ease of sleep,
- fermented wheat extract produced in Example 2 was mixed with a commercially available product as an alcohol-degrading function-enhanced food, and the ability to relieve sore throat as a new effect was examined.
- the current “drink and breath” contains a mixture of green tea extract and green tea extract, but the amount of lipopolysaccharide, one of the active ingredients of plant extract, is only 0.002 g per packet. Degree. Therefore, it is expected to acquire a new function by adding a proper amount of fermented wheat extract with a high lipopolysaccharide content. It is desirable to mix lipopolysaccharide, one of the active ingredients of fermented wheat extract, with 30 g (5 to 150 g of fermented wheat extract) per 1 gram of 2 sachets. First, 50 g of fermented wheat extract per sachet. Manufactured a product containing. In the manufacturing process of drinking and breathing, 2.5 mg of fermented wheat extract produced in Example 2 was prepared per lOOg product. As a result, 50 g of fermented wheat extract per 2 g of product Including new products manufactured.
- the fermented wheat extract produced in Example 2 was dissolved in distilled water, and 0.2 ml per mouse was orally administered to a mouse using a sonde. Ninety minutes later, 0.7% acetic acid was intraperitoneally administered to the mice, and after 5 minutes, the number of writhing that occurred in 30 minutes was measured. The results are shown in Table 16 as the amount of each sample necessary to inhibit the number of writhing in the control with distilled water by 30%. When the effective activity of low molecular weight lipopolysaccharide derived from Escherichia coli was defined as 1, the fermented wheat extract was 7, indicating that the fermented wheat extract exhibits excellent analgesic activity.
- a type I allergy model was introduced.
- a group of 3 to 4 male BALB / c mice were intravenously administered with 1 ⁇ g / mouse of anti-ditropel and mouse monoclonal antibody.
- the fermented wheat extract (4 g / mouse) produced in Example 2 was administered intraperitoneally or orally (100 g / mouse).
- 0.25% A dinitrofluorobenzene-containing acetone oliveol mixed solution (4 to 1) was applied as an allergen.
- the thickness of the pinna at 1, 2, 24, and 48 hours was measured with a thickness gauge, and the difference ( ⁇ ) from the thickness immediately before application was regarded as the degree of edema.
- the effects of drug administration were evaluated based on the suppression rate obtained by the following formula: early response observed 1 hour after allergen administration and delayed response induced 24 hours later.
- ⁇ Inhibition rate (1 auricular edema / dose after administration / control auricular edema) X 100 ⁇
- Table 17 As can be seen, the fermented wheat flour suppressed allergic reactions both intradermally and orally.
- MRSA mesitylin-resistant Staphylococcus aureus
- the fermented solution of 5 was extracted by heating in an autoclave at 120 ° C for 20 minutes. This was centrifuged (Kubota 8800, 2000 rpm, 10 minutes), and the supernatant was collected to obtain Okara fermentation extract.
- a 48-well plate was filled with THP 1 (1 ⁇ 10 6 cells / 250 1: 10% urine fetal serum RPMI1640 medium) used as human macrophages and pre-cultured for 30 minutes in advance.
- Medium 250 ⁇ l final amount 500 ⁇ l was added so that the final concentration of each sample was 100-lOOOOngZml.
- a group containing polymyxin ⁇ (12.5 ⁇ g / ml) was provided in the sample (no group containing only 100 ng / ml polymyxin B). After culturing for 4 hours, the culture supernatant and cells were collected. The TNF activity of the supernatant was measured by L 929 cytotoxicity test. The results are shown in Table 21.
- Table 2 1 TNF production from macrophages by Okara fermented extract and inhibitory effect by polymyxin B (TNF inducing activity of Okara fermented extract) TNF inducing activity of Okara fermented extract and inhibitory effect by polymyxin B (TNF activity)
- the rice flour fermentation solution of 5 was extracted by heating in an autoclave at 120 ° C for 20 minutes. This was subjected to centrifugal separation (Kubota 8800, 2000 rpm, 10 minutes), and the supernatant was collected to obtain a fermented rice flour extract.
- the Limulus active substance amount was determined by using the Toxicolor System of Seikagaku Corporation and Seikagaku Corporation E t 1 as the standard Limulus active substance.
- the limulus active substance content in the fermented rice flour extract was measured as 1.7; ⁇ / ⁇ 1.
- a 48-well plate was filled with ⁇ ⁇ -1 (1X10 6 cells / 2501: 10% urine fetal serum RPMI1640 medium), an acute myeloid leukemia cell line used as human macrophages, and pre-cultured for 30 minutes in advance.
- Medium 250 1 (final amount 500 ⁇ 1) was added so that the final concentration of each sample was 1 lOOOOngZml.
- a group containing polymyxin ⁇ (12.5 ⁇ g / ml) was placed in the sample. After culturing for 4 hours, the culture supernatant and cells were collected. After culturing for 4 hours, the culture supernatant and cells were collected. The TNF activity of the supernatant was measured by L 929 cytotoxicity test.
- the Limulus active substance amount was determined by using the Toxicolor System of Seikagaku Corporation and Seikagaku Corporation E t 1 as the standard Limulus active substance.
- the limulus active substance content in the seaweed kame fermentation extract was determined to be 132 g / ml.
- Table 2 TNF production from macrophages by Wakame kame fermentation extract and inhibitory effect by polymyxin B (TNF inducing activity of wakame kame fermentation extract)
- a plant fermentation extract which is a safe immunostimulatory substance, at low cost
- the plant fermentation extract thus obtained can be used for mammals including humans (specifically, domestic animals, pets). Animals, etc.), birds (specifically poultry, pets, etc.), amphibians, reptiles, fish (specifically, aquaculture fish, pets, etc.), invertebrate medicines, veterinary medicines, pharmaceuticals It can be used for quasi-drugs, cosmetics, foods, functional foods, feed and bath preparations.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Agronomy & Crop Science (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005514195A JP4026722B2 (ja) | 2003-09-26 | 2004-09-22 | 植物発酵エキス、植物発酵エキス末及び該植物発酵エキス配合物 |
KR1020067005875A KR101228993B1 (ko) | 2003-09-26 | 2004-09-22 | 발효 및 배양 방법, 식물발효 엑기스, 식물발효 엑기스분말 및 이 식물발효 엑기스 배합물 |
CN2004800277714A CN1856568B (zh) | 2003-09-26 | 2004-09-22 | 发酵和培养的方法、植物发酵提取物、植物发酵提取物粉末以及含有植物发酵提取物的组合物 |
ES04787995.2T ES2542986T3 (es) | 2003-09-26 | 2004-09-22 | Método de fermentación y cultivo, extracto vegetal fermentado, polvo de extracto vegetal fermentado y composición que contiene el extracto vegetal fermentado |
AU2004276123A AU2004276123B2 (en) | 2003-09-26 | 2004-09-22 | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract |
CA2537890A CA2537890C (en) | 2003-09-26 | 2004-09-22 | Fermentation and culture method using pantoea agglomerans, and fermentedwheat extract and composition containing the fermented wheat extract |
US10/572,853 US8075928B2 (en) | 2003-09-26 | 2004-09-22 | Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant |
EP04787995.2A EP1676908B1 (en) | 2003-09-26 | 2004-09-22 | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract |
IL174166A IL174166A (en) | 2003-09-26 | 2006-03-07 | Method for fermentation of plant material and fermented plant material extract and uses thereof |
NO20061742A NO340880B1 (no) | 2003-09-26 | 2006-04-20 | Fremgangsmåte for fermentering og dyrkning, fermentert planteekstrakt,fermentert planteekstraktpulver og blanding inneholdende det fermenterte planteekstraktet. |
HK07103454.6A HK1096119A1 (en) | 2003-09-26 | 2007-03-30 | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract |
US13/296,551 US9394513B2 (en) | 2003-09-26 | 2011-11-15 | Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant |
NO20170687A NO342031B1 (no) | 2003-09-26 | 2017-04-25 | Fremgangsmåte for fermentering og dyrking, fermentert planteekstrakt, fermentert planteekstraktpulver og blanding inneholdende det fermenterte planteekstraktet |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-336555 | 2003-09-26 | ||
JP2003336555 | 2003-09-26 | ||
JP2004139761 | 2004-05-10 | ||
JP2004-139761 | 2004-05-10 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/572,853 A-371-Of-International US8075928B2 (en) | 2003-09-26 | 2004-09-22 | Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant |
US13/296,551 Division US9394513B2 (en) | 2003-09-26 | 2011-11-15 | Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005030938A1 true WO2005030938A1 (ja) | 2005-04-07 |
Family
ID=34395609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/013812 WO2005030938A1 (ja) | 2003-09-26 | 2004-09-22 | 発酵及び培養方法、植物発酵エキス、植物発酵エキス末並びに該植物発酵エキス配合物 |
Country Status (14)
Country | Link |
---|---|
US (2) | US8075928B2 (ja) |
EP (2) | EP2444480B1 (ja) |
JP (4) | JP4026722B2 (ja) |
KR (2) | KR101228993B1 (ja) |
CN (2) | CN102671009B (ja) |
AU (1) | AU2004276123B2 (ja) |
CA (1) | CA2537890C (ja) |
ES (2) | ES2599830T3 (ja) |
HK (1) | HK1096119A1 (ja) |
IL (1) | IL174166A (ja) |
NO (2) | NO340880B1 (ja) |
NZ (1) | NZ586941A (ja) |
RU (1) | RU2370532C2 (ja) |
WO (1) | WO2005030938A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007284397A (ja) * | 2006-04-18 | 2007-11-01 | Toshie Yasuda | 機能性組成物の製造方法 |
CN100406552C (zh) * | 2006-04-03 | 2008-07-30 | 西北农林科技大学 | 一株成团泛菌及其发酵培养方法与应用 |
JP2008255108A (ja) * | 2007-03-11 | 2008-10-23 | Genichiro Soma | 発酵及び培養方法、ソバ又はレンコン発酵エキス及び発酵エキス配合物 |
JP2010241945A (ja) * | 2009-04-05 | 2010-10-28 | Genichiro Soma | リポ多糖、イネ発酵エキス及びイネ発酵エキス配合物 |
JP2010254578A (ja) * | 2009-04-21 | 2010-11-11 | Genichiro Soma | 小麦発酵抽出物配合物 |
WO2010150867A1 (ja) | 2009-06-25 | 2010-12-29 | キリンホールディングス株式会社 | 穀類植物由来材料発酵物及び免疫調節剤 |
JP2012240946A (ja) * | 2011-05-18 | 2012-12-10 | Genichiro Soma | 植物発酵抽出物配合物 |
JP2013136787A (ja) * | 2005-11-28 | 2013-07-11 | Genichiro Soma | リポ多糖、リポ多糖製造方法及びリポ多糖配合物 |
JP2013179876A (ja) * | 2012-02-29 | 2013-09-12 | Bio Medical Research Group:Kk | キノコ発酵エキス |
JP2013208112A (ja) * | 2012-02-29 | 2013-10-10 | S-Tec Co Ltd | 発酵及び培養方法、エリンギ発酵エキス並びにその配合物 |
JP2013255469A (ja) * | 2012-06-13 | 2013-12-26 | Genichiro Soma | ソルガム発酵エキス |
JP2018044038A (ja) * | 2016-09-12 | 2018-03-22 | 有限会社バイオメディカルリサーチグループ | リポ多糖、リポ多糖製造方法及びリポ多糖配合物 |
JP2020065490A (ja) * | 2018-10-24 | 2020-04-30 | 株式会社アンチエイジング・プロ | Lps高含有組成物の製造方法 |
WO2023248374A1 (ja) * | 2022-06-22 | 2023-12-28 | 源一郎 杣 | 糖尿病性認知症に対する予防薬及び治療薬 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004276123B2 (en) * | 2003-09-26 | 2008-06-26 | Biomedical Research Group Inc. | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract |
KR100737862B1 (ko) * | 2006-07-07 | 2007-07-12 | 학교법인 계명대학교 | 주류생산부산물인 주박과 신규한 바실러스 속 균주를함유한 기능성 유기질비료 |
JP5719497B2 (ja) * | 2008-03-27 | 2015-05-20 | 源一郎 杣 | 飼料添加剤、飼料、その製造方法、斃死予防剤、及び飼育方法 |
JP5207313B2 (ja) * | 2008-05-30 | 2013-06-12 | 有限会社バイオメディカルリサーチグループ | 乳酸菌配合物及びその製造方法 |
EP2489270A4 (en) * | 2009-09-28 | 2013-06-26 | Genichiro Soma | PLANT BREEDING AGENT, RESISTANCE INDUCTOR FOR PLANT HARVEST AND METHOD OF COMBATING PLANT HAZARD |
CN103889396B (zh) * | 2011-08-17 | 2017-08-01 | 巴斯夫公司 | 基于海洋的化妆品活性成分及其用途 |
KR101484587B1 (ko) | 2012-05-22 | 2015-01-26 | 경상대학교산학협력단 | 미역귀와 멍게껍질의 혼합물 추출액을 포함하는 아토피성 피부염 개선용 조성물 |
JP6145352B2 (ja) * | 2013-07-17 | 2017-06-07 | 濱田 奈保子 | 納豆菌を用いたマコンブ発酵物の血圧上昇抑制剤 |
US10595535B2 (en) * | 2014-02-10 | 2020-03-24 | Ibex Bionomics Llc | Bio-derived compositions for use in agriculture |
US10595536B2 (en) * | 2014-02-10 | 2020-03-24 | Ibex Bionomics Llc | Bio-derived compositions |
CN105217803B (zh) * | 2015-11-05 | 2017-09-26 | 北京博汇特环保科技股份有限公司 | 一种污水处理用芽孢杆菌促进剂及其制备方法 |
JP6530776B2 (ja) * | 2017-04-10 | 2019-06-12 | 大川 博 | Fgf−7又はvegf産生促進剤及びその配合物 |
JP6998133B2 (ja) | 2017-05-28 | 2022-01-18 | 自然免疫制御技術研究組合 | リポ多糖を用いた脳機能改善剤、食品及び医薬品 |
JP7349614B2 (ja) * | 2020-01-08 | 2023-09-25 | 株式会社カネヒロデンシ | 害獣捕獲用餌、害獣捕獲用餌の製造方法、及び害獣捕獲用給餌方法 |
CN114514973B (zh) * | 2022-02-17 | 2023-09-05 | 华南农业大学 | 一种具有醒酒护肝功效的葛根复合发酵饮料的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0472467A2 (en) | 1990-08-20 | 1992-02-26 | Chiba Flour Milling Co. Ltd. | LPS-Containing analgesics and veterinary analgesics |
JPH0678756A (ja) | 1990-08-20 | 1994-03-22 | Chiba Seifun Kk | Lps産生菌、lps、lpsを含む医薬及び動物薬 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1185335A (en) * | 1967-05-30 | 1970-03-25 | Takeda Chemical Industries Ltd | A method for producing Protease |
JPS597293B2 (ja) | 1977-05-20 | 1984-02-17 | 協和醗酵工業株式会社 | 新規な食品素材 |
JPS59146539A (ja) | 1983-02-10 | 1984-08-22 | Shikishima Seipan Kk | 菓子類の品質改良法 |
JPS61146142A (ja) * | 1984-12-21 | 1986-07-03 | 長野 宏子 | 発酵剤 |
US5236709A (en) | 1989-02-06 | 1993-08-17 | Chiba Flour Milling Co., Ltd. | Limulus test-positive plant glycolipid and method of stimulating the immunity system of an animal |
JPH03218466A (ja) | 1989-02-06 | 1991-09-26 | Chiba Seifun Kk | リムラステスト陽性植物糖脂質、それらを含む免疫機能活性化剤、動物用免疫機能活性化剤、免疫機能検査薬、動物用免疫機能検査薬、医薬部外品、化粧品、食品、機能性食品、飲料、飼料 |
JPH0449240A (ja) | 1990-06-15 | 1992-02-18 | Chiba Seifun Kk | 抗消化性潰瘍剤、動物用抗消化性潰瘍剤 |
JPH0690745A (ja) | 1990-08-20 | 1994-04-05 | Chiba Seifun Kk | Lps産生菌、lps、lpsを含む医薬及び動物薬 |
US5281583A (en) | 1990-08-20 | 1994-01-25 | Den'ichi Mizuno | LPS-containing analgesics and veterinary analgesics |
JPH0640937A (ja) | 1990-08-20 | 1994-02-15 | Chiba Seifun Kk | Lpsを含む鎮痛剤及び動物用鎮痛剤 |
JPH0499481A (ja) | 1990-08-20 | 1992-03-31 | Chiba Seifun Kk | 新規細菌、新規lps、新規免疫機能活性化剤、新規動物用免疫機能活性化剤 |
JPH04187640A (ja) | 1990-11-22 | 1992-07-06 | Chiba Seifun Kk | 経口・経皮免疫機能促進剤、動物用経口・経皮免疫機能促進剤 |
JPH05155778A (ja) | 1991-12-02 | 1993-06-22 | Chiba Seifun Kk | Lpsを含む発育促進剤及び動物用発育促進剤 |
JP3118761B2 (ja) | 1992-03-13 | 2000-12-18 | 山崎製パン株式会社 | サワー種の調製方法及びサワー種用乳酸菌の栄養培地 |
JP4043533B2 (ja) | 1995-01-27 | 2008-02-06 | 水野 傳一 | 低分子量リポポリサッカライド |
JPH08245702A (ja) | 1995-03-13 | 1996-09-24 | Denichi Mizuno | 高分子量リポポリサッカライド |
JPH09173052A (ja) | 1995-07-12 | 1997-07-08 | Nisshin Flour Milling Co Ltd | 発酵用培地原料の製造法 |
US5776756A (en) * | 1995-08-31 | 1998-07-07 | Toyo Hakko Co., Ltd. | Fermentation compositions having superoxide dismutating activity and an antihypertensive agent for treatment of constipation each having the superoxide dismutating activity |
KR100217222B1 (ko) * | 1997-02-25 | 1999-10-01 | 박민규 | 폐수처리용 미생물제재 제조방법 |
KR100252197B1 (ko) * | 1997-09-20 | 2000-04-15 | 박호군 | 세라시아 마르세센스 균주의 배양액으로 부터 분리한 면역억제제용 프로디지오신 |
CN100473284C (zh) | 1999-03-26 | 2009-04-01 | 杣源一郎 | 用于甲壳类或鱼类的饲料添加剂及饲料 |
JP4599726B2 (ja) * | 2001-02-20 | 2010-12-15 | 味の素株式会社 | L−グルタミン酸の製造法 |
JP2003230375A (ja) * | 2002-02-06 | 2003-08-19 | House Foods Corp | 合成樹脂製ダーラム管 |
US20030203454A1 (en) * | 2002-02-08 | 2003-10-30 | Chotani Gopal K. | Methods for producing end-products from carbon substrates |
AU2004276123B2 (en) * | 2003-09-26 | 2008-06-26 | Biomedical Research Group Inc. | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract |
EP1961823B1 (en) * | 2005-11-28 | 2024-06-12 | Biomedical Research Group Inc. | Method for producing lipopolysaccharide and lipopolysaccharide |
JP2008002044A (ja) * | 2006-06-22 | 2008-01-10 | Satoko Kobayashi | ゴム手袋のずり落ち防止具 |
-
2004
- 2004-09-22 AU AU2004276123A patent/AU2004276123B2/en active Active
- 2004-09-22 KR KR1020067005875A patent/KR101228993B1/ko active IP Right Grant
- 2004-09-22 CA CA2537890A patent/CA2537890C/en active Active
- 2004-09-22 ES ES11009396.0T patent/ES2599830T3/es active Active
- 2004-09-22 RU RU2006114032/13A patent/RU2370532C2/ru active
- 2004-09-22 JP JP2005514195A patent/JP4026722B2/ja active Active
- 2004-09-22 EP EP11009396.0A patent/EP2444480B1/en active Active
- 2004-09-22 US US10/572,853 patent/US8075928B2/en active Active
- 2004-09-22 CN CN201110295578.0A patent/CN102671009B/zh active Active
- 2004-09-22 KR KR1020127004454A patent/KR20120031522A/ko active Search and Examination
- 2004-09-22 NZ NZ586941A patent/NZ586941A/en not_active IP Right Cessation
- 2004-09-22 WO PCT/JP2004/013812 patent/WO2005030938A1/ja active Application Filing
- 2004-09-22 CN CN2004800277714A patent/CN1856568B/zh active Active
- 2004-09-22 EP EP04787995.2A patent/EP1676908B1/en active Active
- 2004-09-22 ES ES04787995.2T patent/ES2542986T3/es active Active
-
2006
- 2006-03-07 IL IL174166A patent/IL174166A/en active IP Right Grant
- 2006-04-20 NO NO20061742A patent/NO340880B1/no unknown
-
2007
- 2007-02-28 JP JP2007050166A patent/JP4704377B2/ja active Active
- 2007-03-30 HK HK07103454.6A patent/HK1096119A1/xx unknown
-
2008
- 2008-02-25 JP JP2008042509A patent/JP4771379B2/ja active Active
-
2011
- 2011-05-06 JP JP2011103776A patent/JP5517215B2/ja active Active
- 2011-11-15 US US13/296,551 patent/US9394513B2/en active Active
-
2017
- 2017-04-25 NO NO20170687A patent/NO342031B1/no unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0472467A2 (en) | 1990-08-20 | 1992-02-26 | Chiba Flour Milling Co. Ltd. | LPS-Containing analgesics and veterinary analgesics |
JPH0678756A (ja) | 1990-08-20 | 1994-03-22 | Chiba Seifun Kk | Lps産生菌、lps、lpsを含む医薬及び動物薬 |
US5494819A (en) | 1990-08-20 | 1996-02-27 | Gen-Ichiro Soma | Pure culture of Pantoea agglomerans ferm BP-3511 |
Non-Patent Citations (12)
Title |
---|
INAGAWA ET AL., ANTICANCER RESEARCH, vol. 17, 1997, pages 2153 - 2158 |
INAGAWA ET AL., BIOTHERAPY, vol. 11, no. 3, 1997, pages 464 - 466 |
INAGAWA ET AL., BIOTHERAPY, vol. 6, no. 3, 1992, pages 358 - 359 |
INAGAWA ET AL., CHEM. PHARM. BULL., vol. 40, no. 4, 1992, pages 994 - 997 |
INAGAWA H. ET AL.: "Anti-tumor effect of lipopolysaccharide by in tradermal administration as a novel drug delivery system", ANTICANCER RESEARCH, vol. 17, no. 3C, 1997, pages 2153 - 2158, XP002904138 * |
INAGAWA H. ET AL.: "Komugi oyobi shoshu gram insei kin yurai lipo tato no keiko toyo ni yoru mouse o mochiita chintsu koka ni hikaku kento", BIOTHERAPY, vol. 6, no. 3, 1992, TOKYO, pages 358 - 359, XP002986288 * |
INAGAWA H. ET AL.: "Pantoea agglomerants LPS(LPSp) no naihi toyo to lipid A yudoitai ONO-4007 no keiko toyo ni yoru IgE izongata allergy hanno no yokusei koka", BIOTHERAPY, vol. 11, no. 3, 1997, TOKYO, pages 464 - 466, XP002986286 * |
NISHIZAWA ET AL., BIOTHERAPY, vol. 6, no. 3, 1992, pages 356 - 357 |
NISHIZAWA T. ET AL.: "Komugi yori bunri shita pantoea agglomerans no seisei lipopolysaccharide no seibutsu kassei ni tsuite no kento", BIOTHERAPY, vol. 6, no. 3, 1992, TOKYO, pages 356 - 357, XP002986287 * |
See also references of EP1676908A4 |
SOMA G.I. ET AL.: "Dynamic aspects of cytokine network to induce antitumor effects by intradermal administration of low molecular weight lipopolysaccharide derived from Pamtoea agglomerans", ADVANCES IN PHARMACEUTICAL SCIENCES, vol. 16, 2000, pages 7 - 22, XP002904139 * |
SOMA, ADVANCES IN PHARMACEUTICAL SCIENCES, vol. 16, 2000, pages 7 - 22 |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5603537B2 (ja) * | 2005-11-28 | 2014-10-08 | 源一郎 杣 | リポ多糖及びリポ多糖製造方法 |
US10017727B2 (en) | 2005-11-28 | 2018-07-10 | Gen-Ichiro Soma | Method for fermentation and culture, fermented plant extract, fermented plant extract composition, method for producing lipopolysaccharide and lipopolysaccharide |
JP2016222923A (ja) * | 2005-11-28 | 2016-12-28 | 源一郎 杣 | リポ多糖、リポ多糖製造方法及びリポ多糖配合物 |
JP2013136787A (ja) * | 2005-11-28 | 2013-07-11 | Genichiro Soma | リポ多糖、リポ多糖製造方法及びリポ多糖配合物 |
CN100406552C (zh) * | 2006-04-03 | 2008-07-30 | 西北农林科技大学 | 一株成团泛菌及其发酵培养方法与应用 |
JP2007284397A (ja) * | 2006-04-18 | 2007-11-01 | Toshie Yasuda | 機能性組成物の製造方法 |
JP2008255108A (ja) * | 2007-03-11 | 2008-10-23 | Genichiro Soma | 発酵及び培養方法、ソバ又はレンコン発酵エキス及び発酵エキス配合物 |
JP2010241945A (ja) * | 2009-04-05 | 2010-10-28 | Genichiro Soma | リポ多糖、イネ発酵エキス及びイネ発酵エキス配合物 |
JP2010254578A (ja) * | 2009-04-21 | 2010-11-11 | Genichiro Soma | 小麦発酵抽出物配合物 |
WO2010150867A1 (ja) | 2009-06-25 | 2010-12-29 | キリンホールディングス株式会社 | 穀類植物由来材料発酵物及び免疫調節剤 |
JP2012240946A (ja) * | 2011-05-18 | 2012-12-10 | Genichiro Soma | 植物発酵抽出物配合物 |
JP2013208112A (ja) * | 2012-02-29 | 2013-10-10 | S-Tec Co Ltd | 発酵及び培養方法、エリンギ発酵エキス並びにその配合物 |
JP2013179876A (ja) * | 2012-02-29 | 2013-09-12 | Bio Medical Research Group:Kk | キノコ発酵エキス |
JP2013255469A (ja) * | 2012-06-13 | 2013-12-26 | Genichiro Soma | ソルガム発酵エキス |
JP2018044038A (ja) * | 2016-09-12 | 2018-03-22 | 有限会社バイオメディカルリサーチグループ | リポ多糖、リポ多糖製造方法及びリポ多糖配合物 |
JP2020065490A (ja) * | 2018-10-24 | 2020-04-30 | 株式会社アンチエイジング・プロ | Lps高含有組成物の製造方法 |
WO2023248374A1 (ja) * | 2022-06-22 | 2023-12-28 | 源一郎 杣 | 糖尿病性認知症に対する予防薬及び治療薬 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4704377B2 (ja) | 発酵及び培養方法、植物発酵エキス、植物発酵エキス末並びに該植物発酵エキス配合物 | |
JP6292725B2 (ja) | リポ多糖、リポ多糖製造方法及びリポ多糖配合物 | |
KR20180018073A (ko) | 항생제 대체용 가축사료첨가제 | |
JP5502449B2 (ja) | 腸内フローラバランス改善剤及びその製造方法 | |
TWI358266B (ja) | ||
TWI458438B (zh) | Fermentation and culture methods, plant fermentation extracts, plant fermentation extract powders, and plant fermentation extract complexes | |
KR20100037309A (ko) | 유산균을 이용한 환형 건강보조식품의 제조방법 | |
KR20060019496A (ko) | 대나무 유래의 미생물을 이용한 발효액 및 그의 제조 방법 | |
KR20240092547A (ko) | 락토코쿠스 락티스를 포함하는 동애등에 추출물 내 비타민 또는 이의 유도체 생성용 조성물 및 이의 용도 | |
KR20240092548A (ko) | 락토바실러스 플란터룸을 포함하는 동애등에 추출물 내 비타민 또는 이의 유도체 생성용 조성물 및 이의 용도 | |
KR20240088546A (ko) | 락토바실러스 브레비스를 포함하는 동애등에 추출물 내 비타민 또는 이의 유도체 생성용 조성물 및 이의 용도 | |
KR20240092546A (ko) | 류코노스톡 메센테로이데스를 포함하는 동애등에 추출물 내 비타민 또는 이의 유도체 생성용 조성물 및 이의 용도 | |
CN115968981A (zh) | 家禽饲料及其制备方法 | |
CN102093964A (zh) | 来自番茄的具有抗氧化和降血脂作用的乳酸菌 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480027771.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2537890 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 174166 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006500579 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005514195 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067005875 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 546551 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 939/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004787995 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006114032 Country of ref document: RU Ref document number: 2004276123 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004276123 Country of ref document: AU Date of ref document: 20040922 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004276123 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067005875 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004787995 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007172492 Country of ref document: US Ref document number: 10572853 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10572853 Country of ref document: US |